Welcome to our dedicated page for Innate Pharma Marseille SEC filings (Ticker: IPHYF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innate Pharma S.A. (IPHYF) SEC Filings provides access to the company’s regulatory disclosures as a foreign private issuer. Innate Pharma S.A. reports to the U.S. Securities and Exchange Commission using Form 20-F and submits Form 6-K current reports that often include press releases as exhibits, such as those dated in September 2025.
On this page, you can review Innate Pharma S.A.’s 6-K and related filings as they are made available through the SEC’s EDGAR system. These documents include current reports that reference press releases, along with detailed financial and structural information prepared under IFRS, covering items such as ordinary and preference shares, issued capital, share premium, retained earnings, accumulated other comprehensive income, and various categories of shareholders.
Filings also describe assets and financing arrangements, including licences, intangible assets under development, land and buildings, laboratory equipment, construction in progress, and right-of-use assets. The disclosures reference loan agreements and lease financing obligations, such as a PGELoanAgreement with Societe Generale and BNP Paribas, and lease obligations for buildings, premises, equipment, vehicles, printers, and other assets.
Stock Titan enhances these filings with AI-powered summaries that help explain the structure and content of lengthy regulatory documents. Users can quickly identify key sections in Innate Pharma S.A.’s 6-K and other filings, see how capital structure and financing are presented, and locate information related to shareholders and counterparties, all without reading every line of the original text.
Innate Pharma reported encouraging interim results from the Phase 2 MATISSE trial of IPH5201 in resectable non-small cell lung cancer. The study combines IPH5201, a first-in-class anti-CD39 antibody, with durvalumab and platinum-based chemotherapy in previously untreated, resectable NSCLC.
In a pre-planned interim analysis of 40 patients, the combination showed higher pathological complete response rates than a benchmark of durvalumab plus chemotherapy alone. Pathological complete response reached 35.7% in tumors with PD-L1 ≥1% and 50% in tumors with PD-L1 ≥50%.
On the basis of these data, MATISSE continues enrolling patients whose tumors express PD-L1 ≥1%. The interim results will be presented in a Clinical Trials Plenary Session at the AACR Annual Meeting 2026, highlighting IPH5201’s potential role in enhancing anti-tumor immune responses in early-stage lung cancer.
Innate Pharma S.A. released an update on its capital structure and voting rights as of April 9, 2026. The company reports 93,860,680 shares outstanding, made up mainly of ordinary shares with small tranches of 2016 and 2017 preferred shares.
The company states it has 94,484,443 theoretical voting rights, used for regulatory threshold calculations in France, and 94,465,868 exercisable voting rights, which exclude treasury shares with suspended voting rights. The update helps clarify shareholder voting power ahead of any future corporate decisions.
Innate Pharma S.A. will hold its Annual General Meeting of shareholders at 10:30 a.m. CEST on May 21, 2026, at its headquarters in Marseille, France. The notice, agenda, proposed resolutions, and voting instructions were published in the French legal bulletin and are available on the company’s investor website.
The AGM will be broadcast live online, and a guided tour of the company’s laboratories will be organized the same day at 9:15 a.m. CEST for shareholders who register in advance. Only shareholders with shares recorded in an account at least five trading days before the meeting, and bearer shareholders providing a broker certificate, will be entitled to participate and vote.
Novo Nordisk A/S reports passive beneficial ownership of 4,718,727 ordinary shares of Innate Pharma. The filing states this position represents 5.03% of the class as of 03/31/2026 and shows sole voting and dispositive power over all 4,718,727 shares. The filing is an amendment to a Schedule 13G/A and is signed by Karsten Munk Knudsen, Chief Financial Officer, on 04/10/2026.
Innate Pharma S.A., a clinical-stage immuno-oncology company listed on Euronext Paris and Nasdaq, announced that Chief Operating Officer Yannis Morel will present at the AACR Oncology Industry Partnering Event in San Diego. The April 16, 2026 showcase session will allow Innate to highlight its oncology pipeline, including key assets such as IPH4502, a Nectin4 antibody-drug conjugate for solid tumors, lacutamab for cutaneous and peripheral T cell lymphomas, and monalizumab, developed with AstraZeneca, for non-small cell lung cancer. The company views this invitation as recognition of its clinical pipeline and an opportunity to engage directly with investors and industry partners.
Innate Pharma S.A., a clinical-stage biotechnology company developing cancer immunotherapies, reported that its executive team will participate in one-on-one investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 15–16, 2026.
The company highlights its portfolio of antibody-based therapies, including IPH4502, lacutamab and monalizumab, and notes ongoing collaborations with major partners such as AstraZeneca and Sanofi. The notice also reiterates that investors should refer to its French Universal Registration Document and Form 20-F for detailed risk factors.
Innate Pharma S.A. has filed its 2025 Universal Registration Document with the French market authority AMF and its 2025 Form 20-F annual report with the U.S. SEC, both covering the year ended December 31, 2025. These filings include the annual financial report, management report, corporate governance report, and statutory auditors’ report.
Innate Pharma is a clinical-stage biotechnology company focused on cancer immunotherapies, developing next-generation antibody-based drugs such as IPH4502, lacutamab and monalizumab, in collaboration with partners including AstraZeneca and Sanofi.
Innate Pharma S.A. files its Form 20‑F annual report, describing a clinical‑stage, oncology‑focused biotech developing immuno‑oncology antibodies, including checkpoint inhibitors and its ANKET® multi‑specific platform. Financial statements are prepared under IFRS Accounting Standards and presented in euros.
The report emphasizes that most product candidates are in early clinical or preclinical stages, with high development uncertainty, reliance on partners AstraZeneca and Sanofi, and significant dependence on additional financing. It highlights extensive regulatory, clinical, competitive and reimbursement risks, and notes orphan drug, fast track, PRIME and Breakthrough Therapy designations for lacutamab as important but not guaranteed paths to faster approval. Ordinary shares outstanding were 93,719,323 as of December 31, 2025.
Innate Pharma S.A. reported a 2025 net loss of €49.2 million, broadly in line with 2024, as revenue and other income fell 55% to €9.0 million mainly due to lower collaboration and licensing revenue from AstraZeneca and Sanofi.
Cash, cash equivalents, short-term investments and financial assets totaled €44.8 million as of December 31, 2025, giving an estimated cash runway only until the end of Q3 2026. Shareholders’ equity turned negative at €(21.7) million, and the company states there is substantial doubt about its ability to continue as a going concern while it pursues non-dilutive financing options.
R&D expenses declined 16% to €43.6 million as the pipeline was strategically refocused, including discontinuation of IPH6501, while key programs such as lacutamab, IPH4502 and partnered assets with AstraZeneca and Sanofi continue to advance toward significant data and regulatory milestones in 2026.
Innate Pharma S.A. filed a Form 6-K to share details of an upcoming conference call and webcast for its full year 2025 financial results. The call will take place on Thursday, March 26, 2026 at 2 p.m. CET / 9 a.m. EDT, following the release of results for the year ended December 31, 2025.
Senior leadership, including the Chief Executive Officer, Chief Medical Officer, Chief Operating Officer, Chief Financial Officer and Vice President of Investor Relations, will participate. The event will be accessible via webcast and telephone, with a replay available on the company’s website for 90 days.